New evidence supports rapidly initiating combination therapy for heart failure with preserved ejection fraction (HFpEF). Starting SGLT inhibitors, finerenone, and GLP-1 receptor agonists early may deliver faster and additive benefits, reducing cardiovascular death or hospitalization while improving patient symptoms and quality of life.